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Background
Langerhans cells (LC), skin residential cells, are shown to
induce specific CD8+ T cell response upon activation. Tar-
geting vaccine antigens to LC with specific antibodies
could elucidate specific CD8+ response. Therefore we pro-
pose the intra-dermal injection of mAb specific for C-type
lectin Langerin, expressed on LC in epidermis, fused to
HIV Gag p24 protein, as type of T-cell based vaccine. The
present work emphasizes molecular and cellular immune
mechanisms triggered in the skin by intra-dermal vaccina-
tion.
Methods
Technical approach considers an intra-dermal injection of
fusion protein (100 μg) in macaque that was followed by
skin and draining lymph nodes (LN) biopsies at different
time points. Frozen biopsies were used for immunochem-
istry fluorescent staining to establish biodistribution of
injected Ab/fusion protein and co-localisation with differ-
ent cell types.
Results
We show that antibody used as delivery system, targeted
and brought p24 antigen specifically to the LC in epider-
mis. Number of targeted LC in the zone of injection
increased in the first days upon injection and peaked 72 h
after injection. In draining LN, HIV Gag p24 were detected
as soon as 4 h after injection. 24 h post injection, fusion
protein appeared to be associated with CD1a+ cells.
Conclusion
Our data suggested that using viral antigens fused to the
mAb specific for LC target and bring viral Ag specifically to
this cell population in the zone of injection. This same
fusion protein related to the CD1a+ cells was present in
draining lymph nodes as soon as 24 h after injection
where it could present viral antigen and activate CD8+ T
lymphocytes.
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